BIO-TECHNE Corp (TECH) : Underhill Investment Management added new position in BIO-TECHNE Corp during the most recent quarter end. The investment management firm now holds 1,900 shares of BIO-TECHNE Corp which is valued at $210,349 , the company said in a statement filed on Jul 26, 2016 with the SEC.BIO-TECHNE Corp makes up approximately 0.11% of Underhill Investment Management’s portfolio.
Other Hedge Funds, Including , Huntington National Bank reduced its stake in TECH by selling 480 shares or 14.22% in the most recent quarter. The Hedge Fund company now holds 2,895 shares of TECH which is valued at $320,505. BIO-TECHNE Corp makes up approx 0.01% of Huntington National Bank’s portfolio.Parkwood reduced its stake in TECH by selling 816 shares or 14.75% in the most recent quarter. The Hedge Fund company now holds 4,718 shares of TECH which is valued at $522,519. BIO-TECHNE Corp makes up approx 0.09% of Parkwood’s portfolio.Ibm Retirement Fund reduced its stake in TECH by selling 28 shares or 0.75% in the most recent quarter. The Hedge Fund company now holds 3,710 shares of TECH which is valued at $410,883. BIO-TECHNE Corp makes up approx 0.01% of Ibm Retirement Fund’s portfolio.
BIO-TECHNE Corp opened for trading at $110.58 and hit $113.09 on the upside on Friday, eventually ending the session at $112.42, with a gain of 1.48% or 1.64 points. The heightened volatility saw the trading volume jump to 2,20,844 shares. Company has a market cap of $4,184 M.
On the company’s financial health, BIO-TECHNE Corp reported $1.01 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.89. The company had revenue of $130.97 million for the quarter, compared to analysts expectations of $122.71 million. The company’s revenue was up 14.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.88 EPS.
Bio-Techne Corporation (Bio-Techne) formerly Techne Corporation develops manufactures and sells biotechnology reagents instruments and clinical diagnostic products around the world. The Company has three business segments: the Biotechnology Clinical Controls and Protein Platforms divisions. The Biotechnology segment develops manufactures and sells biotechnology research and diagnostic products around the world. The Clinical Controls segment develops and manufactures controls and calibrators for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. Bio-Techne is engaged in providing specialized proteins including cytokines and growth factors antibodies related immunoassays biologically active small molecules and other reagents to the research diagnostics and clinical controls markets.